Hitclav-LB 625 Tablet is a combination antibiotic formulation containing Amoxycillin 500 mg, Clavulanic Acid 125 mg, and Lactobacillus spores equivalent to 60 million CFU. Amoxycillin, a broad-spectrum penicillin antibiotic, acts by inhibiting bacterial cell wall synthesis, effectively targeting susceptible Gram-positive and Gram-negative bacteria. Clavulanic Acid serves as a beta-lactamase inhibitor, preventing enzymatic degradation of Amoxycillin by resistant bacterial strains, thereby enhancing its antimicrobial efficacy. The inclusion of Lactobacillus spores helps maintain and restore normal gut flora, reducing the risk of antibiotic-associated diarrhea and other gastrointestinal disturbances commonly observed during antibiotic therapy. Hitclav-LB 625 is indicated for the treatment of various bacterial infections including respiratory tract infections, urinary tract infections, skin and soft tissue infections, and otitis media caused by beta-lactamase producing organisms. It is essential to use this medication under medical supervision with appropriate dosage adjustments based on infection severity and patient-specific factors such as renal function. Caution is advised in patients with a history of penicillin allergy or hypersensitivity. Adverse effects may include gastrointestinal discomfort, hypersensitivity reactions, and rarely, hepatic dysfunction. This combination therapy offers a synergistic approach to effectively manage resistant bacterial infections while supporting gastrointestinal health.